Biogen Inc. (BIIB)
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript
Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss
Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi
BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.
Here Are Monday's Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John's International, Shopify, and More
Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street.
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position.
